CCA
RYTM icon

Catalyst Capital Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Catalyst Capital Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-321
Closed -$9K – 557
2017
Q4 		$9K Buy
+321
New +$8.49K ﹤0.01% 347

Other funds holding RYTM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Catalyst Capital Advisors's RYTM Position: Q1 2018 in Review

Catalyst Capital Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2018, closing a stake of 321 shares — an estimated $9K sold.

Catalyst Capital Advisors first reported a position in RYTM in Q4 2017 and held it in 1 quarter. The position peaked at $9K in Q4 2017. 55 funds tracked by Wall St. Rank hold RYTM as of Q1 2018.

  • Catalyst Capital Advisors reported no remaining Rhythm Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 321 Rhythm Pharmaceuticals shares in Q1 2018, an estimated $9K.
  • Catalyst Capital Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Catalyst Capital Advisors's Rhythm Pharmaceuticals position peaked at $9K in Q4 2017.
  • 55 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2018.

Based on Catalyst Capital Advisors's 13F filing for Q1 2018, filed 18 May 2018.